Latest Octreotide Stories
NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally.
Octreotide provides benefits for both the liver and kidney in patients with ADPKD.
EAST HANOVER, N.J., Oct.
- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of Glivec(R)...
LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com.
- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain patients with newly diagnosed neuroendocrine tumors (NETs) EAST HANOVER, N.J., Jan.
Company to Host Conference Call January 6, 2009 at 8:30 a.m. EST LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has entered into a definitive merger agreement under which Endo Pharmaceuticals Holdings, Inc.
Acquisition Adds Marketed Products and Specialty Sales Force in Urology and Endocrinology, Novel Drug-Delivery Technology Combined Pipeline to Include Nine FDA-Approved Therapeutics Conference Call Scheduled for Today at 5:30 pm EST CHADDS FORD, Pa. and LEXINGTON, Mass., Jan.
Ambrilia Biopharma Inc. (TSX: AMB) today reported positive 24-week extension Phase III ("Study 302") top line results for its proprietary prolonged-release formulation of octreotide C2L. Overall, the results support the safety of C2L over an additional period of 6 months.
LEXINGTON, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced the initiation of a Phase III clinical trial of the Company's novel octreotide implant for acromegaly.
- The word or words serving to define another word or expression, as in a dictionary entry.